drugset / Trial / NCT07560449
QLS4131 Combination Therapy in Malignant Plasma Cell Neoplasms
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of the study is to compare the efficacy of QLS4131(SC) in combination with QL2109, with or without pomalidomide or lenalidomide, and QLS4131 (SC) in combination with QL2109, and QLS4131 (SC) in combination with Pomalidomide, and QLS4131(SC) in combination with QL2109 and Lenalidomide.
Timeline
- Start
- 2026-06
- Primary completion
- 2028-06
- Completion
- 2030-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenalidomide | Other / unclassified | — | Oral |
| Subject | Pomalidomide | Other / unclassified | — | Oral |
| Subject | QL2109 | Monoclonal antibody | — | Subcutaneous |
| Subject | QLS4131 | Monoclonal antibody | — | Subcutaneous |
| Background | Dexamethasone | Small molecule | — | Oral |